Home Press Office BEAUTIFUL Study

Recruitment and baseline data of the BEAUTIFUL Study


Demographic and general medical characteristics of the randomized population at baseline



Comorbidities



Cardiovascular characteristics of the randomized population at baseline



Concomitant medications taken at baseline, expressed as percentage of randomized patients


In the BEAUTIFUL study, patients received the optimal medical treatments as recommended in the guidelines, with high prescription rates of beta-blockers (87%), renin-angiotensin system agents (89%), antiplatelet agents (84%), serum lipid–lowering agents (76%), and diuretics (55%).


  • The rates for beta-blockers and lipid–lowering drugs were higher than the 67 and 52%, respectively, found in the Euro Heart Survey of Stable Angina.
  • The rate of beta-blocker use in BEAUTIFUL was the same as in the recent COURAGE2 trial of optimal medical therapy in stable coronary artery disease patients and in most of the cases had no history of heart failure(mean left ventricular ejection fraction = 61%).
  • The rates of use of renin-angiotensin system agents and beta-blockers were also higher than the 66.3 and 36.9%, respectively, found in the Euro Heart Survey3 on Heart Failure.

Distribution of resting heart rate at baseline in patients taking and not taking beta-blockers.


At baseline, the overall population had a mean resting heart rate of 71.6 bpm: 71.1 bpm in patients taking beta-blockers, and 74.1 bpm in those not taking beta-blockers. Overall, 50% of patients had resting heart rate slightly >70 bpm at baseline; the distribution of baseline resting heart rate among patients is shown below:


References
1. The BEAUTIFUL Study Group.The BEAUTIFUL study: randomized trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction—baseline characteristics of the study population. Cardiology. 2008;110:271-282 .
2. Boden, WE et al. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med 2007;35:1503-1516.
3. Daly et al. The initial management of stable angina in Europe, from The euro Heart Survey. European Heart Journal, 2005;26,1011-22

top